

RANBAXY MOROCCO LLC SARLAU

REPORT OF THE INDEPENDENT AUDITOR

FISCAL YEAR ENDED MARCH 31, 2014

Report of independent auditors

As of March 31, 2014

To the Shareholder of RANBAXY MOROCCO LLC SARLAU

We have audited the financial statements here attached of **RANBAXY MOROCCO LLC SARLAU** which include the balance sheet, the income statement here attached for the year ended as at March 31, 2014. These financial statements show a **negative net equity of 470** thousands of Moroccan Dirhams including a **net loss of 5.239** thousands of Moroccan Dirhams.

Management's Responsibility

Management is responsible for the preparation and fair presentation of these financial statements in accordance with generally accepted accounting principles and standards in Morocco. This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation of financial statements that are free from material misstatement and making accounting estimates that are reasonable in the circumstances.

Auditors' Responsibility

Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with generally accepted auditing standards in Morocco. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial statements in order to design audit procedures that are

appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall financial statements presentation.

We believe that the audit evidence that we have obtained is sufficient and appropriate to provide a reasonable basis for our audit opinion.

Opinion on the financial statements

In our opinion the financial statements mentioned in the first paragraph above give, in all their significant aspects, a fair view of the financial situation of the company **RANBAXY MOROCCO LLC SARLAU** as at March 31, 2014 as well as the result of its operations for the year then ended, in accordance with Moroccan accounting standards.

Without disputing the above opinion, we bring to your attention the following situation.

- Subsequent to the decision of the sole shareholder dated 26/03/2014, the closing date of the accounts of Ranbaxy Morocco LLC SARLAU is no longer the 31 of December but the 31 of March. This year being the first time this change is applied, the financial statements here attached comprise 15 months of activity from January 2013 to March 2014, whereas the comparative period comprise 12 months of activity from January 2012 to December 2013.
- We bring your attention to article 86 of the law 5-96 (Law on LLCs) according to which the shareholder has decided on April, 20th 2012 not to liquidate the company and to continue operations despite the negative equity. Therefore, and according to the same law, the shareholder has proceeded to an increase of capital of **11 435 thousands** of Moroccan dirhams to clear the situation with respect to year ended December, 31st 2011.
- The balance sheet and the profit and loss account as at March 31, 2014 have been prepared assuming that **Ranbaxy Morocco LLC SARLAU** will continue its operations despite the negative equity of **469 thousands** of Moroccan Dirhams. The management of the company considers that the shareholder will continue to provide the necessary support to Ranbaxy Morocco LLC SARLAU so that it will be able to continue operations.

- As of March, 31st 2014 equity has become negative which brings the company in the same situation as December, 31st 2011 with respect to article 86 of the law 5-96 (Law on LLCs). Consequently, the shareholder must decide within 3 months of the decision which approves accounts here attached whether the company should be liquidated. If the shareholder decides the company should not be liquidated, he must, before the year ended March, 31st 2015, either reduce share capital by the amount of losses, or create reserves through earnings or an increase of capital, so that equity becomes at least equal to one fourth (25%) of share capital.

Casablanca, 02 May 2014

THE INDEPENDENT AUDITOR

Chakib Zaari

Réviséa Casablanca SARL

RANBAXY MOROCCO LLC
SOCIETE A RESPONSABILITE LIMITEE D' ASSOCIE UNIQUE
Au capital de 800.000,00 Dirhams
Siège social : 169 Bd Hassan I
Casablanca
R.C Casablanca 231.541 – Identifiant fiscal 40256039

MANAGEMENT REPORT

-Fiscal Year 2013

Sir,

The present Management Report has been established in conformity with the provisions of the law 5-96 relating in particular to limited liability companies and to the bylaws of the company in order to present you the activities of the company during the second fiscal year ended on December 31st 2013, results of these activities and its economic outlook in view to submit to your approval the balance sheet and the annual accounts.

1- ANALYSIS AND COMMENTS REGARDING THE ACTIVITIES

During the year, the company strengthened its market presence in Morocco pharmaceutical market led by strong growth in business of its existing products. The company is now ranked 57th in the private pharmaceutical market of Morocco as per IMS Dec 2013. Further the company launched two new brands - Viarect (Sildenafil) and Cilentra (Escitalopram) in market in proceeded with the local manufacturing of Viarect , Ceroxim and Ceruvin using its plant.

During the year, the company got Market Authorizations for 6 brands from Ministry of Health – Baxmune (Mycophenolate), Femolet (Letrozole), Ranozyp (Olanzapine), Ranpirole (Ropinorole), Romilast (Monteleukast) and Ran-Simva (Simvastatin). All the brands will launched after pricing approval in next financial year.

The company also won tender from Ministry of health for its entire Anti-retrovirals range in Morocco of MAD 8,541,900.00 INR 60,537,916, thereby developing its position as one of the leading pharmaceutical companies in Morocco for supply of essential medicines to Ministry of Health

Capital increase of MAD 11,435,300 INR 83,347,668 by converting RNBV loan to equity

The losses incurred during 2013 are MAD 4,517,495.73 INR 32,016,270 which leads the accumulated loss to MAD 11,983,151.59 INR 84,926,659 funded by equity and loan from parent company to the tune of 4,899,920 USD, MAD 40,311,641.84 INR 293,816,631.

We ask you to approve the annual accounts of fiscal year ended on December 31st 2013 as they are presented to you which show a accumulated loss of MAD 11,983,151.59 INR 84,926,659.

2- EXAMINATION OF ANNUAL ACCOUNTS AND RESULTS

Hereinafter we present to you in details the summary of financial statements of the fiscal year ended on December 31st 2013 which we submit for your acceptance.

Presentation rules and accounting methods of evaluation for the establishment of these documents are in compliance with the legislation in force.

In the course of fiscal year 2013

- The company has realized a turnover of MAD 42,860,256.17 INR 303,758,017;
- Total operating incomes are of MAD 51,795,663.39 INR 367,084,787;
- Total operating and administrative charges are of MAD 56,643,447.12 INR 401,441,864.78;
- Net operating income of (4,847,783.73) INR (34,357,078);
- Fiscal year ended on December 31st 2013 shows a loss of MAD 4,517,495.73 INR 32,016,270;

3- REGULATED AGREEMENTS REGARDING TO THE ARTICLE 64 OF THE LAW 5-96

During the fiscal year, the company has concluded with its parent company "RANBAXY (Netherlands) B.V." a loan agreement of USD 3,500,000 INR 209,580,838.

4- PROPOSAL OF RESULTS ALLOCATION

We propose to decide to carry forward the loss of fiscal year ended on December 31st 2013 for an amount of 4,517,495.73 INR 32,016,270.

Moreover, we suggest you to decide the continuation of the company despite the existence of the losses that make the net equity of the company less than on quarter of the registered share capital.

5- ECONOMIC OUTLOOK

In 2014/2015, the company will get more Market Authorizations which are under approval process at the ministry of Health, to increase its sales and profitability. This will allow Ranbaxy Morocco LLC to strengthen its presence in Morocco.

We are staying at your disposal for any clarification requests and for any further information.

At last, we hope that you shall agree with previous elements and that you shall vote positively the following resolutions which are now presented to you.

Casablanca, April 30, 2014

A Manager

Atul CHHABRA

RANBAXY MOROCCO LLC
SOCIETE A RESPONSABILITE LIMITEE D' ASSOCIE UNIQUE
Au capital de 12.235.300,00 Dirhams
Siège social : 169 Bd Hassan I
Casablanca
R.C Casablanca 231.541 – Identifiant fiscal 40256039

MANAGEMENT REPORT

-Fiscal Year Q1 2014

Sir,

The present Management Report has been established in conformity with the provisions of the law 5-96 relating in particular to limited liability companies and to the bylaws of the company in order to present you the activities of the company during the third fiscal year ended on March 31st 2014, results of these activities and its economic outlook in view to submit to your approval the balance sheet and the annual accounts.

1- ANALYSIS AND COMMENTS REGARDING THE ACTIVITIES

During the year, the company strengthened its market presence in Morocco pharmaceutical market led by strong growth in business of its existing products. The company is now ranked 57th in the private pharmaceutical market of Morocco as per IMS March 2014.

During the quarter, the company got Market Authorizations for 3 brands from Ministry of Health – Corpril (Ramipril), Oxovasin (Sodium Chloride), Adosine (Didanozine). All the brands will launched after pricing approval in next financial year.

Capital increase on 26th of March 2014 of MAD 11 435 300 INR 83,347,668 by converting RNBV loan to equity

The losses incurred during Q1 2014 are MAD 721,688.33 INR 5,114,727 which leads the accumulated loss to MAD 12,704,839.92 INR 90,041,382 funded by equity to the tune of USD 1 497 192,00 MAD 12,235,300.00 INR 89,178,571 and loan from parent company to the tune of 3,499,968 USD , MAD 28,608,738.43 INR 208,518,498.

We ask you to approve the annual accounts of fiscal year ended on March 31st 2014 as they are presented to you which show a accumulated loss of MAD 12,704,839.92 INR 90,041,382.

2- EXAMINATION OF ANNUAL ACCOUNTS AND RESULTS

Hereinafter we present to you in details the summary of financial statements of the fiscal year ended on March 31st 2014 which we submit for your acceptance.

Presentation rules and accounting methods of evaluation for the establishment of these documents are in compliance with the legislation in force.

In the course of fiscal year Q1 2014

- The company has realized a turnover of MAD 12,015,451.61 INR 85,155,575;
- Total operating incomes are of MAD 12,792,749.71 INR 90,664,420;
- Total operating and administrative charges are of MAD 13,581,407.84 INR 96,253,776;
- Net operating income of MAD (788,658.13) INR(5,589,356);
- Fiscal year ended on March 31st 2014 shows a loss of MAD 721,688.33 INR 5,114,727;

3- REGULATED AGREEMENTS REGARDING TO THE ARTICLE 64 OF THE LAW 5-96

During the fiscal year, the company did not conclude any regulated agreement with the mother company.

4- PROPOSAL OF RESULTS ALLOCATION

We propose to decide to carry forward the loss of fiscal year ended on March 31st 2014 for an amount of MAD 721,688.33 INR 5,114,727.

Moreover, we suggest you to decide the continuation of the company despite the existence of the losses that make the net equity of the company less than on quarter of the registered share capital.

5- ECONOMIC OUTLOOK

In 2014/2015, the company will get more Market Authorizations which are under approval process at the ministry of Health, to increase its sales and profitability. This will allow Ranbaxy Morocco LLC to strengthen its presence in Morocco.

We are staying at your disposal for any clarification requests and for any further information.

At last, we hope that you shall agree with previous elements and that you shall vote positively the following resolutions which are now presented to you.

Casablanca, April 30, 2014

A Manager

Atul CHHABRA

Balance Sheet (Assets)

In Moroccan Dirhams

	ASSETS	CURRENT YEAR			PRIOR YEAR
		Gross Amount	Amortisation or depreciation	Net amount	Net amount
	CAPITALIZED EXPENSES (A)	163,353.00	51,870.60	111,482.40	19,200.00
	Preliminary expenses	163,353.00	51,870.60	111,482.40	19,200.00
F	Deferred expenses on several years	0.00	0.00	0.00	0.00
I	Premium of debentures refund	0.00	0.00	0.00	0.00
X	INTANGIBLE FIXED ASSETS (B)	3,006.00	501.00	2,505.00	0.00
E	Research and development	0.00	0.00	0.00	0.00
D	Patents, Trademarks, and similar rights	3,006.00	501.00	2,505.00	0.00
	Goodwill	0.00	0.00	0.00	0.00
A	Other Intangible Assets	0.00	0.00	0.00	0.00
S	TANGIBLE FIXED ASSETS(C)	911,415.18	130,506.01	780,909.17	320,932.92
S	Land	0.00	0.00	0.00	0.00
E	Buildings	0.00	0.00	0.00	0.00
T	Industrial fixtures and equipment	27,055.82	6,087.56	20,968.26	24,350.24
S	Transportation equipment	0.00	0.00	0.00	0.00
	Office equipment and furniture	884,359.36	124,418.45	759,940.91	296,582.68
	Other tangible fixed assets	0.00	0.00	0.00	0.00
	Tangible fixed assets in progress	0.00	0.00	0.00	0.00
	LONG TERM INVESTMENTS (D)	525,572.74	0.00	525,572.74	103,955.50
	Long term loans	0.00	0.00	0.00	0.00
	Other financial assets	525,572.74	0.00	525,572.74	103,955.50
	Investments	0.00	0.00	0.00	0.00
	Other investments	0.00	0.00	0.00	0.00
	UNREALISED EXCHANGE RATE LOSSES (Non Current)	0.00		0.00	0.00
	Unrealised exchange rate losses (from long term assets)	0.00		0.00	0.00
	Unrealised exchange rate losses (from long term liabilities)	0.00		0.00	0.00
	TOTAL I (A+B+C+D+E)	1,603,346.92	182,877.61	1,420,469.31	444,088.42
C	INVENTORIES (F)	10,546,038.43	498,009.35	10,048,029.08	4,288,316.08
U	Merchandises	1,483,904.90	0.00	1,483,904.90	0.00
R	Raw materials and furnitures	5,429,452.73	202,302.41	5,227,150.32	2,979,809.46
R	Work in progress	431,572.40	295,706.94	135,865.46	1,308,506.62
E	Intermediate and residual products	0.00	0.00	0.00	0.00
N	Finished products	3,201,108.40	0.00	3,201,108.40	0.00
T	CURRENT ASSETS(G)	30,250,175.64	0.00	30,250,175.64	20,316,732.17
A	Advances payments to suppliers and other debtors	552,599.91	0.00	552,599.91	21,272.09
S	Trade accounts receivable	26,245,694.58	0.00	26,245,694.58	18,500,304.07
S	Personnel	229,162.14	0.00	229,162.14	9,203.65
E	Taxes	3,185,034.01	0.00	3,185,034.01	1,657,814.84
T	Shareholders Current accounts	0.00	0.00	0.00	0.00
	Others debtors	36,420.00	0.00	36,420.00	124,100.02
	Deferral accounts	1,265.00	0.00	1,265.00	4,037.50
	MARKETABLE SECURITIES (H)	0.00		0.00	0.00
	UNREALISED EXCHANGE RATE LOSSES (I)	48,301.00		48,301.00	105,966.22
	(Current)	0.00		0.00	0.00
	TOTAL II (F+G+H+I)	40,844,515.07	498,009.35	40,346,505.72	24,711,014.47
C	CASH AND CASH EQUIVALENTS (Assets)	17,095,833.14	0.00	17,095,833.14	7,410,507.05
A	Checks and other instruments to be cashed	0.00	0.00	0.00	0.00
S	Cash on Bank	17,084,132.55	0.00	17,084,132.55	7,409,620.29
H	Cash on hand	11,700.59	0.00	11,700.59	886.76
	TOTAL III	17,095,833.14	0.00	17,095,833.14	7,410,507.05
				0.00	
	TOTAL ASSETS I+II+III	59,543,695.13	680,886.96	58,862,808.17	32,565,609.94

INCOME STATEMENT

In Moroccan Dirhams

	ITEM	CURRENT YEAR			PRIOR YEAR	
		related to the period	related to the prior periods	Net amount	Net amount	
		1	2	3=2+1	4	
O P E R A T I V I N G	I OPERATING REVENUE					
	Sales of merchandise	54,875,707.78	0.00	54,875,707.78	23,665,373.59	
	Sales of goods and services	0.00	0.00	0.00	0.00	
	Turnover	54,875,707.78	0.00	54,875,707.78	23,665,373.59	
	Finished Goods inventory change (+/-) (1)	2,028,888.34	0.00	2,028,888.34	1,603,792.46	
	Self constructed capital asset	0.00	0.00	0.00	0.00	
		0.00	0.00	0.00	0.00	
	Operating Subsidy					
	Others operating income	6,739,832.81	0.00	6,739,832.81	1,563,738.30	
	Reversal of operating provisions-charges transfer	943,984.17	0.00	943,984.17	4,250.00	
	TOTAL I	64,588,413.10	0.00	64,588,413.10	26,837,154.35	
II	OPERATING EXPENSES					
	Purchase of goods for resale (2)	28,324,794.58	0.00	28,324,794.58	17,010,945.48	
	Purchase of materials and supplies (2)	10,040,511.84	38,980.50	10,079,492.34	2,384,783.14	
	Other external expenses	18,749,618.61	287,369.67	19,036,988.28	7,246,488.30	
	Taxes	1,581,541.32	3,159.89	1,584,701.21	1,258,691.67	
	Personnel expenses	10,045,521.89	0.00	10,045,521.89	3,848,442.30	
	Other operating expenses	0.00	0.00	0.00	0.00	
	Operating allowances (for depreciation and risks)	1,153,356.66	0.00	1,153,356.66	327,291.03	
		TOTAL II	69,895,344.90	329,510.06	70,224,854.96	32,076,641.92
	III OPERATING INCOME / LOSS (I - II)			-5,636,441.86	-5,239,487.57	
F I N A N C I A L	IV FINANCIAL REVENUE					
	Revenue from investment and others					
	Exchange gains	1,156,063.13	22,914.54	1,178,977.67	7,684.21	
	Interests and other financial revenue	0.00	0.00	0.00	0.00	
	Reversal of financial provisions - charges transfer	57,665.22	0.00	57,665.22	60,198.16	
		TOTAL IV	1,213,728.35	22,914.54	1,236,642.89	67,882.37
	V FINANCIAL EXPENSES					
	Interests expenses	699,695.32	0.00	699,695.32	243,563.61	
	Exchange losses	21,107.94	0.00	21,107.94	4,668.46	
	Other financial expenses	0.00	0.00	0.00	0.00	
Financial allowances	0.00	0.00	0.00	105,966.22		
	TOTAL V	720,803.26	0.00	720,803.26	354,198.29	
	VI FINANCIAL INCOME (IV-V)			515,839.63	-286,315.92	
	VII ORDINARY INCOME (III+VI)			-5,120,602.23	-5,525,803.49	

1) Change in inventories: final inventories - initial inventories, increase (+) decrease (-)

2) Cost: purchases - inventories change

	ITEM				
	VII ORDINARY INCOME (report)			-5,120,602.23	-5,525,803.49
	VIII EXCEPTIONAL REVENUE				
	Revenue from assets disposal			0.00	
	Balancing Subsidy			0.00	
	Reversal of Investment Subsidy			0.00	
	Other extraordinary revenue	467.20		467.20	122.19
	Reversal of extraordinary provisions- charges transfer			0.00	
	TOTAL VIII	467.20	0.00	467.20	122.19
N O N C U R R E N T	IX EXCEPTIONAL EXPENSES				
	Net value of sold assets	0.00		0.00	0.00
	Granted Subsidies	0.00		0.00	0.00
	Others extraordinary expenses	53,184.03		53,184.03	19,816.42
	Extraordinary allowances	0.00		0.00	0.00
	TOTAL IX	53,184.03	0.00	53,184.03	19,816.42
	X EXCEPTIONAL INCOME / LOSS (VIII - IX)			-52,716.83	-19,694.23
	XI INCOME / LOSS BEFORE TAXES(VII + X)			-5,173,319.06	-5,545,497.72
	XII INCOME TAX			65,865.00	0.00
	XIII NET INCOME / LOSS (XI - XII)			-5,239,184.06	-5,545,497.72
	XIV TOTAL OF REVENUES (I+IV+VII)			65,825,523.19	26,905,158.91
	XV TOTAL OF EXPENSES (II+V+IX+XIII)			71,064,707.25	32,450,656.63
	XVI NET INCOME			-5,239,184.06	-5,545,497.72

Balance Sheet (Assets)

IN INR

ASSETS		CURRENT YEAR			PRIOR YEAR
		Gross Amount	Amortisation or depreciation	Net amount	Net amount
CAPITALIZED EXPENSES (A)		1,190,717.13	378,096.59	812,620.54	124,432.92
	Preliminary expenses	1,190,717.13	378,096.59	812,620.54	124,432.92
F	Deferred expenses on several years	0.00	0.00	0.00	
I	Premium of debentures refund	0.00	0.00	0.00	
INTANGIBLE FIXED ASSETS (B)		21,911.42	3,651.90	18,259.51	
E	Research and development	0.00	0.00	0.00	
D	Patents, Trademarks, and similar rights	21,911.42	3,651.90	18,259.51	
	Goodwill	0.00	0.00	0.00	
A	Other Intangible Assets	0.00	0.00	0.00	
TANGIBLE FIXED ASSETS(C)		6,643,512.29	951,287.95	5,692,224.34	2,079,928.19
S	Land	0.00	0.00	0.00	
E	Buildings	0.00	0.00	0.00	
T	Industrial fixtures and equipment	197,216.02	44,373.61	152,842.41	157,811.02
S	Transportation equipment	0.00	0.00	0.00	
	Office equipment and furniture	6,446,296.27	906,914.35	5,539,381.93	1,922,117.17
	Other tangible fixed assets	0.00	0.00	0.00	
	Tangible fixed assets in progress	0.00	0.00	0.00	
LONG TERM INVESTMENTS (D)		3,831,019.09	0.00	3,831,019.09	673,723.27
	Long term loans	0.00	0.00	0.00	
	Other financial assets	3,831,019.09	0.00	3,831,019.09	673,723.27
	Investments	0.00	0.00	0.00	
	Other investments	0.00	0.00	0.00	
UNREALISED EXCHANGE RATE LOSSES (Non Current)		0.00	0.00	0.00	
	Unrealised exchange rate losses (from long term assets)	0.00	0.00	0.00	
	Unrealised exchange rate losses (from long term liabilities)	0.00	0.00	0.00	
TOTAL I (A+B+C+D+E)		11,687,159.93	1,333,036.44	10,354,123.48	2,878,084.38
		0.00	0.00	0.00	
INVENTORIES (F)		76,872,469.82	3,630,103.28	73,242,366.54	27,792,067.92
C	Merchandises	10,816,519.91	0.00	10,816,519.91	
U	Raw materials and furnitures	39,576,514.34	1,474,628.22	38,101,886.11	19,311,791.70
R	Work in progress	3,145,829.26	2,155,475.06	990,354.20	8,480,276.22
R	Intermediate and residual products	0.00	0.00	0.00	
E	Finished products	23,333,606.31	0.00	23,333,606.31	
CURRENT ASSETS(G)		220,500,402.06	0.00	220,500,402.06	131,670,331.63
T	Advances payments to suppliers and other debtors	4,028,026.28	0.00	4,028,026.28	137,861.89
	Trade accounts receivable	191,310,829.93	0.00	191,310,829.93	119,898,276.54
A	Personnel	1,670,414.90	0.00	1,670,414.90	59,647.76
S	Taxes	23,216,436.43	0.00	23,216,436.43	10,744,101.36
S	Shareholders Current accounts	0.00	0.00	0.00	
E	Others debtors	265,473.65	0.00	265,473.65	804,277.51
T	Deferral accounts	9,220.87	0.00	9,220.87	26,166.56
MARKETABLE SECURITIES (H)		0.00	0.00	0.00	
UNREALISED EXCHANGE RATE LOSSES (I)		352,076.96	0.00	352,076.96	686,754.50
	(Current)	0.00	0.00	0.00	
TOTAL II (F+G+H+I)		297,724,948.84	3,630,103.28	294,094,845.56	160,149,154.05
		0.00	0.00	0.00	
CASH AND CASH EQUIVALENTS (Assets)		124,615,411.35	0.00	124,615,411.35	48,026,617.30
A	Checks and other instruments to be cashed	0.00	0.00	0.00	
S	Cash on Bank	124,530,123.10	0.00	124,530,123.10	48,020,870.32
H	Cash on hand	85,288.26	0.00	85,288.26	5,746.99
TOTAL III		124,615,411.35	0.00	124,615,411.35	48,026,617.30
		0.00	0.00	0.00	
TOTAL ASSETS I+II+III		434,027,520.12	4,963,139.73	429,064,380.40	211,053,855.74

Balance Sheet (Liabilities)

	LIABILITIES	CURRENT YEAR	PRIOR YEAR
C A P I T A L A N D R E S E R V E S	Shareholder's equity (A)		
	* Common stock (1)	89,185,881.15	5,184,705.12
	* (Minus) Common stock subscribed but not called-up called-up capital Paid-in capital : 800,000.00	0.00	5,184,705.12
	* Issuance, merger and contribution premium	0.00	
	* Revaluation reserve	0.00	
	* Legal reserve	0.00	
		0.00	
	* Others reserves	0.00	
	* Profit/ loss account brought forward (2)	-55,469,591.03	-12,444,317.17
	* Not yet allocated income (2)	0.00	
	* Net income / loss of the year	-37,138,873.26	-34,358,721.93
	Total Shareholders Net Equity (A)	-3,422,583.14	-41,618,333.99
	RELATED EQUITY (B)	0.00	
	* Investment Subsidy	0.00	
	* Regulatory provisions	0.00	
		0.00	
		0.00	
		0.00	
	FINANCIAL LIABILITIES (C)	0.00	
	* Debenture Loans	0.00	
* Other financial liabilities	0.00		
	0.00		
	0.00		
	0.00		
PROVISION FOR CONTINGENCIES AND LOSSES(D)	0.00	0.00	
Provision for contingencies	0.00		
Provision for losses	0.00		
UNREALISED EXCHANGE RATE GAINS (Non current) (E)	0.00		
Unrealised exchange rate gains from long term assets	0.00		
Unrealised exchange rate gains from long term liabilities	0.00		
	0.00		
Total I (A+B+C+D+E)	-3,422,583.14	-41,618,333.99	
	0.00		
L I A B I L I T I E S	CURRENT LIABILITIES (F)	429,259,896.79	249,727,926.83
	Trade accounts payable	191,592,760.03	159,683,798.96
	Clients in credit, Advance payments received	2,462,716.35	
	Personnel	5,430,862.10	2,462,917.76
	Social security liabilities	5,054,261.26	2,076,373.56
	Taxes	11,038,157.75	7,432,529.75
	Shareholders current accounts	213,660,751.32	78,051,587.30
	Others debts	20,387.97	20,719.51
	Deferral accounts	0.00	
	OTHER PROVISION FOR CONTINGENCIES AND LOSSES (G)	352,076.96	686,754.50
UNREALISED EXCHANGE RATE GAINS (Current) (H)	2,874,989.79	2,257,508.39	
Total II (F+G+H)	432,486,963.54	252,672,189.72	
	0.00		
C A S H	CASH LIABILITIES	0.00	
	Discounts credit	0.00	
	Short term credit facility	0.00	
	Bank Overdrafts	0.00	
Total III	0.00		
	0.00		
TOTAL LIABILITIES I+II+III	429,064,380.40	211,053,855.74	

(1) Debtor share capital (-)

(2) Income (+) Loss (-)

INCOME STATEMENT

	ITEM	CURRENT YEAR			PRIOR YEAR
		related to the period	related to the prior periods	Net amount	Net amount
		1	2	3=2+1	3=2+1
O P E R A T I N G	I OPERATING REVENUE				
	Sales of merchandise	388,996,059.86	0.00	388,996,059.86	146,625,610.84
	Sales of goods and services	0.00	0.00	0.00	
	Turnover	388,996,059.86	0.00	388,996,059.86	146,625,610.84
	Finished Goods inventory change (+/-) (1)	14,382,130.13	0.00	14,382,130.13	9,936,756.26
	Self constructed capital asset	0.00	0.00	0.00	
		0.00	0.00	0.00	
	Operating Subsidy	0.00	0.00	0.00	
	Others operating income	47,776,484.59	0.00	47,776,484.59	9,688,589.22
	Reversal of operating provisions-charges transfer	6,691,597.02	0.00	6,691,597.02	26,332.09
		0.00	0.00	0.00	
	TOTAL I	457,846,271.60	0.00	457,846,271.60	166,277,288.41
	O P E R A T I N G	II OPERATING EXPENSES	0.00	0.00	0.00
Purchase of goods for resale (2)		200,785,264.26	0.00	200,785,264.26	105,396,192.57
Purchase of materials and supplies (2)		71,173,925.64	276,320.10	71,450,245.73	14,775,608.05
Other external expenses		132,909,953.39	2,037,070.21	134,947,023.59	44,897,697.03
Taxes		11,211,032.47	22,399.43	11,233,431.91	7,798,585.32
Personnel expenses		71,209,440.25	0.00	71,209,440.25	23,844,128.25
Other operating expenses		0.00	0.00	0.00	
Operating allowances (for depreciation and risks)		8,175,770.56	0.00	8,175,770.56	2,027,825.46
		0.00	0.00	0.00	
TOTAL II		495,465,386.57	2,335,789.74	497,801,176.31	198,740,036.68
	III OPERATING INCOME / LOSS (I - II)	0.00	0.00	-39,954,904.71	-32,462,748.27
F I N A N C I A L	IV FINANCIAL REVENUE	0.00	0.00	0.00	
	Revenue from investment and others	0.00	0.00	0.00	
	Exchange gains	8,194,955.85	162,433.73	8,357,389.58	47,609.73
	Interests and other financial revenue	0.00	0.00	0.00	
	Reversal of financial provisions - charges transfer	408,770.01	0.00	408,770.01	372,974.97
		0.00	0.00	0.00	
	TOTAL IV	8,603,725.86	162,433.73	8,766,159.58	420,584.70
	V FINANCIAL EXPENSES	0.00	0.00	0.00	
	Interests expenses	4,959,912.75	0.00	4,959,912.75	1,509,068.22
	Exchange losses	149,627.33	0.00	149,627.33	28,924.78
Other financial expenses	0.00	0.00	0.00		
Financial allowances	0.00	0.00	0.00	656,544.11	
	0.00	0.00	0.00		
TOTAL V	5,109,540.08	0.00	5,109,540.08	2,194,537.11	
	VI FINANCIAL INCOME (IV-V)	0.00	0.00	3,656,619.51	-1,773,952.42
	VII ORDINARY INCOME (III+VI)	0.00	0.00	-36,298,285.20	-34,236,700.68

1)Change in inventories: final inventories - initial inventories, increase (+) decrease (-)
2) Cost: purchases - inventories change

	ITEM	CURRENT YEAR			PRIOR YEAR
		related to the period	related to the prior periods	Net amount	Net amount
		1	2	3=2+1	3=2+1
	VII ORDINARY INCOME (report)	0.00	0.00	-36,298,285.20	-34,236,700.68
E X C E P T I O N A L	VIII EXCEPTIONAL REVENUE	0.00	0.00	0.00	
	Revenue from assets disposal	0.00	0.00	0.00	
	Balancing Subsidy	0.00	0.00	0.00	
	Reversal of Investment Subsidy	0.00	0.00	0.00	
	Other extraordinary revenue	3,311.83	0.00	3,311.83	757.06
	Reversal of extraordinary provisions- charges transfer	0.00	0.00	0.00	
	TOTAL VIII	3,311.83	0.00	3,311.83	757.06
E X C E P T I O N A L	IX EXCEPTIONAL EXPENSES	0.00	0.00	0.00	
	Net value of sold assets	0.00	0.00	0.00	
	Granted Subsidies	0.00	0.00	0.00	
	Others extraordinary expenses	377,004.31	0.00	377,004.31	122,778.31
	Extraordinary allowances	0.00	0.00	0.00	
	TOTAL IX	377,004.31	0.00	377,004.31	122,778.31
	X EXCEPTIONAL INCOME / LOSS (VIII - IX)	0.00	0.00	-373,692.48	-122,021.25
	XI INCOME / LOSS BEFORE TAXES(VII + X)	0.00	0.00	-36,671,977.68	-34,358,721.93
	XII INCOME TAX	0.00	0.00	466,895.58	
	XIII NET INCOME / LOSS (XI - XII)	0.00	0.00	-37,138,873.26	
		0.00	0.00	0.00	
	XIV TOTAL OF REVENUES (+IV+VII)	0.00	0.00	466,615,743.01	166,698,630.17
	XV TOTAL OF EXPENSES (II+V+IX+XIII)	0.00	0.00	503,754,616.27	201,057,352.11
	XVI NET INCOME	0.00	0.00	-37,138,873.26	-34,358,721.93

Note : Conversion rate used against Indian Rupees for the year 2014/2013 and 2012 are:

i) Items relating to Profit and Loss account at Average rate: 1 MAD= 0.1411 [2012: 1 Euro =0.1614]

ii) Items relating to Balance sheet at Closing rate: 1 Euro = 0.1372 [2012: 1 Euro=0.1543]